Synthesis and biological evaluation of novel pyridazinone-based α4 integrin receptor antagonists

Journal of Medicinal Chemistry

Volumn 49, Issue 11, 2006, Pages 3402-3411

  Gong, Yong ^a   Barbay, J Kent ^a   Dyatkin, Alexey B ^a   Miskowski, Tamara A ^a   Kimball, Edward S ^a   Prouty, Stephen M ^a   Fisher, M Carolyn ^a   Santulli, Rosemary J ^a   Schneider, Craig R ^a   Wallace, Nathaniel H ^a   Ballentine, Scott A ^a   Hageman, William E ^a   Masucci, John A ^a   Maryanoff, Bruce E ^a   Damiano, Bruce P ^a   Andrade Gordon, Patricia ^a   Hlasta, Dennis J ^a   Hornby, Pamela J ^a   He, Wei ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 TERT BUTOXYCARBONYLAMINO 3 [4 [2 (2 HYDROXYETHYL) 5 METHOXY 3 OXO 2,3 DIHYDROPYRIDAZIN 4 YL]PHENYL]PROPIONIC ACID 2 HYDROXYETHYL ESTER; ALPHA4 INTEGRIN; ANTIINFLAMMATORY AGENT; DEXTRAN SULFATE; INTEGRIN RECEPTOR; INTEGRIN RECEPTOR ANTAGONIST; PYRIDAZINONE DERIVATIVE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL ADHESION; COLITIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LYMPHOCYTE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; CELL ADHESION; COLITIS; DEXTRAN SULFATE; ENDOTHELIAL CELLS; ESTERS; GRANULOCYTES; HUMANS; IMMUNOGLOBULINS; INTEGRIN ALPHA4BETA1; INTEGRINS; K562 CELLS; LYMPHOCYTES; MICE; MONOCYTES; MUCOPROTEINS; PHENYLALANINE; PRODRUGS; PYRIDAZINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; UMBILICAL VEINS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 33744798761     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060031q     Document Type: Article

References (33)

1. Yusuf-Makagiansar, H.; Anderson, M. E.; Yakovleva, T. V.; Murray, J. S.; Siahaan, T. J. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med. Res. Rev. 2002, 22, 146-167.
2. 4 Integrins as therapeutic targets in autoimmune disease. N. Engl. J. Med. 2003, 348, 68-72.
3. Miller, D. H.; Khan, O. A.; Sheremata, W. A.; Blumhardt, L. D.; Rice, G. P. A.; Libonati, M. A.; Willmer-Hulme, A. J.; Dalton, C. M.; Miszkiel, K. A.; O'Connor, P. W. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2003, 348, 15-23.
4. FDA press release P04-107, November 23, 2004. http://www.fda.gov/bbs/ topics/news/2004/NEW01141.html (accessed January 2006).
5. (a) Biogen Idec and Elan Corporation press release, February 28, 2005. http://www.elan.com/News/full.asp?ID=679361 (accessed January 2006).
6. (b) Podolsky, D. K. Selective adhesion-molecule therapy and inflammatory bowel disease - a tale of Janus? N. Engl. J. Med. 2005, 353, 1965-1967.
7. Following completion of a safety evaluation, Biogen Idec and Elan submitted to the FDA in September 2005 a supplemental Biologics License Application supporting market re-entry of Tysabri; an FDA advisory committee voted unanimously in March 2006 to recommend its reintroduction.
8. (a) Ghosh, S.; Goldin, E.; Gordon, F. H.; Malchow, H. A.; Rask-Madsen, J.; Rutgeerts, P.; Vyhnálek, P.; Zádorová, Z.; Palmer, T.; Donoghue, S. Natalizumab for active Crohn's disease. N. Engl. J. Med. 2003, 348, 24-32.
9. (b) Sandborn, W. J.; Colombel, J. F.; Enns, R.; Feagan, B. G.; Hanauer, S. B.; Lawrance, I. C.; Panaccione, R.; Sanders, M.; Schreiber, S.; Targan, S.; van Deventer, S.; Goldblum, R.; Despain, D.; Hogge, G. S.; Rutgeerts, P. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 2005, 353, 1912-1925.
10. 7 integrin. N. Engl. J. Med. 2005, 352, 2499-2507.
11. Reviews: (a) Tilley, J. W.; Sidduri, A. VLA-4 antagonists. Drugs Future 2001, 26, 985-998.
12. (b) Yang, G. X.; Hagmann, W. K. VLA-4 antagonists: potent inhibitors of lymphocyte migration. Med. Res. Rev. 2003, 23, 369-392.
13. (c) Jackson, D. Y. Alpha 4 integrin antagonists. Curr. Pharm. Des. 2002, 8, 1229-1253.
14. 7 integrin antagonists and their potential as anti-inflammatory agents. J. Med. Chem. 2002, 45, 3451-3457.
15. 1 integrin antagonist. Bioorg. Med. Chem. 2002, 10, 2051-2066.
16. 4 integrin antagonists: (a) Hagmann, W. K.; Durette, P. L.; Lanza, T.; Kevin, N. J.; de Laszlo, S. E.; Kopka, I. E.; Young, D.; Magriotis, P. A.; Li, B.; Lin, L. S.; Yang, G.: Kamenecka, T.; Chang, L. L.; Wilson, J.; MacCoss, M.; Mills, S. G.; Van Riper, G.; McCauley, E.; Egger, L. A.; Kidambi, U.; Lyons, K.; Vincent, S.; Stearns, R.; Colletti, A.; Teffera, J.; Tong, S.; Fenyk-Melody, J.; Owens, K.; Levorse, D.; Kim, P.; Schmidt, J. A.; Mumford, R. A. The discovery of sulfonylated dipeptides as potent VLA-4 antagonists. Bioorg. Med. Chem. Lett. 2001, 11, 2709-2713.
17. (b) Yang, G. X.; Chang, L. L.; Truong, Q.; Doherty, G. A.; Magriotis, P. A.; de Laszlo, S. E.; Li, B.; MacCoss, M.; Kidambi, U.; Egger, L. A.; McCauley, E.; Van Riper, G.; Mumford, R. A.; Schmidt, J. A.; Hagmann, W. K. N-Tetrahydrofuroyl-(L)-phenylalanines as potent VLA-4 antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 1497-1500.
18. Gong, Y.; He, W. Direct synthesis of unprotected 4-aryl phenylalanines via the Suzuki reaction under microwave irradiation. Org. Lett. 2002, 4, 3803-3805.
19. Maes, B. U. W.; R'kyek, O.; Kosmrlj, J.; Lemiere, G. L. F.; Esmans, E.; Rozenski, J.; Dommisse, R. A.; Haemers, A. Suzuki reactions on chloropyridazinones: an easy approach towards arylated 3(2H)-pyridazinones. Tetrahedron 2001, 57, 1323-1330.
20. Nucleophilic substitution of 5-alkoxypyridazinones (as byproduct): Kweon, D.-H.; Kang, Y.-J.; Chung, H.-A.; Yoon, Y.-J. Dehalogenation of 1-methyl-5-halo-4-substituted-pyridazin-6-ones. J. Heterocycl. Chem. 1998, 35, 819-826.
21. 4 integrins mediate initial attachment, and E-selectin mediates rolling. J. Immunol. 1999, 163, 343-350.
22. 4 integrins. J. Immunol. 2003, 170, 5704-5711.
23. Cell-cell adhesion assays were conducted by Cerep, Poitiers, France.
24. (a) Vaporciyan, A. A.; Jones, M. L.; Ward, P. A. Rapid analysis of leukocyte-endothelial adhesion. J. Immunol. Methods. 1993, 159, 93-100.
25. (b) Kapiotis, S.; Quehenberger, P.; Sengoelge, G.; Pärtan, C.; Eher, R.; Strobl, H.; Bevec, D.; Zapolska, D.; Schwarzinger, I.; Speiser, W. Modulation of pyrogen-induced upregulation of endothelial cell adhesion molecules (CAMs) by interleukin-4: Transcriptional mechanisms and CAM-shedding. Circ. Shock 1994, 43, 18-25.
26. (c) Staunton, D. E.; Dustin, M. L.; Springer, T. A. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 1989, 339, 61-64.
27. The absence of observable plasma concentrations of ester prodrugs is consistent with rapid hydrolysis, which may have occurred in blood or other compartments. However, the possibility of incomplete hydrolysis at the time of withdrawal of blood samples and continued hydrolysis during storage at -70 °C and/or extraction of plasma samples cannot be excluded; therefore, observed concentrations of carboxylic acid drugs following prodrug administration are best interpreted as an upper limit of the actual concentration in blood at the time of collection.
28. Huryn, D. M.; Ashwell, S.; Baudy, R.; Dressen, D. B.; Gallaway, W.; Grant, F. S.; Konradi, A.; Ley, R. W.; Petusky, S.; Pleiss, M. A.; Sarantakis, D.; Semko, C. M.; Sherman, M. M.; Tio, C.; Zhang, L. Synthesis, characterization and evaluation of pro-drugs of VLA-4 antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 1651-1654.
29. Stella, V. J. Prodrugs as therapeutics. Expert Opin. Ther. Pat. 2004, 14, 277-280.
30. 1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis. J. Pharmacol. Exp. Ther. 2003, 305, 1150-1162.
31. Cho, S.-D.; Choi, W.-Y.; Yoon, Y.-J. Concurrent alkylation-methoxylation of 4,5-dihalopyridazin-6-ones and synthesis of 5-halo-4-hydroxypyridazin-6-ones. J. Heterocycl. Chem. 1996, 33, 1579-1582.
32. Pilgram, K. H.; Pollard, G. E. 4(and 5)-Cyclopropylamino-5(and 4)-halo-3(2H) pyridazinones. Formation and characterization of isomers. J. Heterocycl. Chem. 1977, 14, 1039-1043.
33. Kimball, E. S.; Wallace, N. H.; Schneider, C. R.; D'Andrea, M. R.; Hornby, P. J. Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulfate sodium induced colitis in mice. Neurogastroenterol. Motility 2004, 16, 811-818.